Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Ascentage Pharma Developed Novel Olverembatinib Drug Candidate to Treat SDH-Deficient GIST

Ascentage Pharma developed olverembatinib (HQP1351), novel drug candidate, for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST) who had obtained first-line treatment.

Olverembatinib, is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with TKI-resistant chronic-phase chronic myeloid leukaemia (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation.

Olverembatinib, is the primary and most effective third-technology BCR-ABL inhibitor authorised in China for the treatment of patients TKI-resistant continual-segment continual myeloid leukaemia (CML-CP) or accelerated-segment CML (CML-AP) harbouring the T315I mutation.

While being clinically evolved and followed for the treatment of haematologic malignancies, olverembatinib additionally possed powerful antitumor response against GIST in preclinical and early medical studies, along with mainly promising efficacy in individuals with SDH-poor GIST.

Results from an ongoing Phase Ib/II study confirmed an excellent scientific gain rate (CBR) of 93.8 percent in sufferers with this subtype of GIST.

GIST is a form of malignancy that arises in mesenchymal tissues of the gastrointestinal tract, and maximum patients with GIST harbor KIT or PDGFRA mutations. The advent of TKIs has extensively stepped forward the diagnosis of these patients. However, patients with SHD-poor GIST, a unprecedented subtype of GIST, nonetheless have extensive unmet clinical needs. Currently, there is no standard of care for patients with relapsed or advanced SDH-deficient GIST.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024